Congress Asset Management Co. Has $33.91 Million Stake in Medpace Holdings, Inc. $MEDP

Congress Asset Management Co. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,378 shares of the company’s stock after selling 4,317 shares during the period. Congress Asset Management Co. owned about 0.21% of Medpace worth $33,911,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC bought a new stake in shares of Medpace during the third quarter worth $25,000. Optiver Holding B.V. bought a new position in shares of Medpace in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares in the last quarter. Quarry LP acquired a new stake in shares of Medpace during the 3rd quarter valued at $35,000. Finally, Employees Retirement System of Texas bought a new stake in Medpace during the 2nd quarter worth $36,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on MEDP. Truist Financial lowered their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Leerink Partners cut their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Finally, Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $486.67.

Insider Buying and Selling

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 20.30% of the company’s stock.

Medpace Stock Up 0.8%

Shares of NASDAQ:MEDP opened at $460.74 on Wednesday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92. The stock’s 50 day moving average is $503.29 and its 200-day moving average is $538.33. The firm has a market capitalization of $13.08 billion, a price-to-earnings ratio of 30.11, a PEG ratio of 2.19 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s revenue was up 32.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.